ISOLOGIC Innovative Radiopharmaceuticals has officially inaugurated its new $30-million facility in Lachine, Quebec, which aims to enhance access to next-generation radiopharmaceuticals for Canadian patients. The investment, part of a commitment to advance nuclear medicine in Canada, will increase production capacity and ensure a reliable supply of radiopharmaceuticals critical for diagnosing and treating serious diseases, including various cancers and neurological disorders. The new facility incorporates advanced technologies and is set to support the growing demand for nuclear medicine. ISOLOGIC currently supplies to nearly 230 hospitals across the country, contributing to the care of over 650,000 patients annually.
Wed, 02 Sep 2026 15:00:00 GMT | BioSpace